Medpace Holdings Inc. (MEDP)
NASDAQ: MEDPHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MEDP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $17.08B
- P/E (TTM)
- 33.90
- Forward P/E
- 30.74
- EPS (TTM)
- $18.01
- Dividend yield
- None
- 52-week range
- 373.00 – 693.97
- Day range
- 606.73 – 633.87
- Volume / Avg
- 236.69K / 257.80K
- Beta
- —
- Shares outstanding
- 27.97M
52-week range
MEDP stock today
Medpace (MEDP) closed at $610.54 on Nov 20, down 3.70% (-$23.44), versus the S&P 500's 3.70% decline. At this level, MEDP sits in the middle of its 52-week range of $373.00 to $693.97: 12.0% below the high, set on Oct 28, 2026 and 63.7% above the low. MEDP is up 8.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 3.2%.
At 33.9x trailing earnings, Medpace trades below the peer-group median of 74.7x. Its forward P/E of 30.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Medpace
Company profileMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Dr. August James Troendle M.D.
- Headquarters
- Cincinnati, OH
- Employees
- 6,600
- IPO year
- 2016
- Website
- medpace.com
Financial highlights
Full financialsIn fiscal 2025, Medpace generated $2.53 billion in revenue, up 20.0% from fiscal 2024, its 10th consecutive year of revenue growth. Net income was $451.1 million (+11.6% year over year), for a net margin of 17.8% versus a median of 15.9% in the prior 5 years. Operating margin was 21.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.53B | $2.11B | $1.89B | $1.46B | $1.14B |
| Growth | +19.97% | +11.84% | +29.17% | +27.80% | +23.38% |
| Net income | $451.12M | $404.39M | $282.81M | $245.37M | $181.85M |
| EPS (diluted) | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 |
Analyst forecast
ForecastConsensus (14 analysts)
none
Avg. price target
$651.31+6.68%
- Strong buy 1
- Buy 1
- Hold 11
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 21, 2026
- EPS actual vs est.
- $3.86 vs $4.45
- Surprise
- -13.26%
MEDP news
All MEDP news- Medpace (MEDP) Down 3.1% Since Last Earnings Report: Can It Rebound?Nasdaq
- CON or MEDP: Which Is the Better Value Stock Right Now?NasdaqCON, MEDP
- Are Options Traders Betting on a Big Move in Medpace Stock?Nasdaq
- Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?NasdaqMEDP, AVIR
- 3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)Nasdaq
- ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock DownNasdaqALC, ISRG, MEDP, GEHC
- NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View UpNasdaqNTRA, ISRG, MEDP, GEHC
- TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal AdvancesNasdaqTECH, ISRG, MEDP, GEHC
Medpace peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRLCharles River Laboratories International Inc. | 314.32 | -4.15% | $15.06B | vs MEDP |
| ICLRICON plc | 186.71 | -1.92% | $13.99B | vs MEDP |
| INCYIncyte Corp. | 114.63 | -1.07% | $23.36B | vs MEDP |
| ABSIAbsci Corporation | 7.51 | -7.97% | $1.30B | vs MEDP |
| OABIOmniAb Inc. | 4.66 | -7.36% | $679.71M | vs MEDP |
| NRCNRC Health | 25.16 | +0.68% | $533.93M | vs MEDP |
| MXCTMaxCyte Inc. | 1.37 | +7.03% | $141.45M | vs MEDP |
| ONMDOneMedNet Corp Class A | 4.70 | +4.21% | $29.15M | vs MEDP |
Indexes, lists and sector
Medpace stock FAQ
What is Medpace's stock price today?
MEDP last traded at $610.54 as of Nov 20, 4:00 PM EST, down 3.70% on the day. Prices are delayed at least 15 minutes.
What is MEDP's P/E ratio?
MEDP trades at a trailing P/E ratio of 33.90 and a forward P/E of 30.74, compared with a median of 74.7 for its closest peers.
Who is Medpace's CEO?
Dr. August James Troendle M.D. is the chief executive officer of Medpace Holdings Inc., which has about 6,600 employees.
What is the MEDP 52-week high?
The 52-week high for MEDP is $693.97 and the 52-week low is $373.00. The stock is currently 12.0% below its high.